TY - JOUR
T1 - β-blockers and breast cancer survival by molecular subtypes
T2 - a population-based cohort study and meta-analysis
AU - Løfling, L. Lukas
AU - Støer, Nathalie C.
AU - Sloan, Erica K.
AU - Chang, Aeson
AU - Gandini, Sara
AU - Ursin, Giske
AU - Botteri, Edoardo
N1 - Funding Information:
This study was funded by the Norwegian Research Council (project number: 301628 to EB), the National Breast Cancer Foundation, Australia (project number: IIRS-20–025 to EKS and EB), and was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds (to SG). The funders had no role in the design of the study, the data collection, the analysis or interpretation of the data, the writing of the article, or the decision to submit the manuscript for publication.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/6/20
Y1 - 2022/6/20
N2 - Background: The association between use of β-blockers and breast cancer (BC) prognosis has been investigated in several observational studies, with conflicting results. We performed a nationwide cohort study and a meta-analysis to investigate the association, and assess if it varied between molecular subtypes of BC. Methods: We identified women aged ≥50 years with BC diagnosed between 2004 and 2018 in Norway. We used Cox regression models to estimate the association between β-blocker use at diagnosis and BC-specific survival, overall and by molecular subtype. We performed a meta-analysis of observational studies that reported molecular subtype-specific estimates of this association. Results: We included 30,060 women, of which 4461 (15%) used β-blockers. After a median follow-up of 5.1 years, 2826 (9%) died of BC. Overall, β-blocker use was not associated with BC-specific survival (hazard ratio [HR] = 1.07; 95% confidence interval [CI]: 0.97–1.19). We found an association only in triple-negative BC (TNBC) patients (HR = 0.66; 95% CI: 0.47–0.91). This was confirmed in the meta-analysis: β-blocker use was associated with progression/recurrence-free (HR = 0.58; 95% CI: 0.38–0.89) and BC-specific survival (HR = 0.74; 95% CI: 0.55–1.00) in TNBC patients only. Conclusion: In our cohort of BC patients and in the meta-analysis, β-blocker use was associated with prolonged BC-specific survival only in TNBC patients.
AB - Background: The association between use of β-blockers and breast cancer (BC) prognosis has been investigated in several observational studies, with conflicting results. We performed a nationwide cohort study and a meta-analysis to investigate the association, and assess if it varied between molecular subtypes of BC. Methods: We identified women aged ≥50 years with BC diagnosed between 2004 and 2018 in Norway. We used Cox regression models to estimate the association between β-blocker use at diagnosis and BC-specific survival, overall and by molecular subtype. We performed a meta-analysis of observational studies that reported molecular subtype-specific estimates of this association. Results: We included 30,060 women, of which 4461 (15%) used β-blockers. After a median follow-up of 5.1 years, 2826 (9%) died of BC. Overall, β-blocker use was not associated with BC-specific survival (hazard ratio [HR] = 1.07; 95% confidence interval [CI]: 0.97–1.19). We found an association only in triple-negative BC (TNBC) patients (HR = 0.66; 95% CI: 0.47–0.91). This was confirmed in the meta-analysis: β-blocker use was associated with progression/recurrence-free (HR = 0.58; 95% CI: 0.38–0.89) and BC-specific survival (HR = 0.74; 95% CI: 0.55–1.00) in TNBC patients only. Conclusion: In our cohort of BC patients and in the meta-analysis, β-blocker use was associated with prolonged BC-specific survival only in TNBC patients.
UR - http://www.scopus.com/inward/record.url?scp=85132204190&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01891-7
DO - 10.1038/s41416-022-01891-7
M3 - Article
AN - SCOPUS:85132204190
SN - 0007-0920
VL - 127
SP - 1086
EP - 1096
JO - British Journal of Cancer
JF - British Journal of Cancer
ER -
